Abstract
Many trypanosomatid protozoa, such as those belonging to the Trypanosoma and Leishmania genera cause serious diseases to man. Such parasites present an unusual feature, a mitochondrial DNA arranged in catenated circles, known as kinetoplast DNA (kDNA). The replication of kDNA network is a complex process, which involves many proteins. Some of them are classified as topoisomerases and play essential biological roles, not only on kDNA synthesis, but also in the dynamics of the network topology, constituting the main target for drugs in kinetoplast. DNA binding drugs are also reported as chemotherapeutic agents against trypanosomatid infections. This review summarizes what is known about kinetoplast as a potential chemotherapeutic target for trypanosomatid protozoa.
Keywords: Chemotherapy, DNA binding drugs, kinetoplast, topoisomerases, trypanosomatids
Current Pharmaceutical Design
Title: Kinetoplast as a Potential Chemotherapeutic Target of Trypanosomatids
Volume: 14 Issue: 9
Author(s): Maria Cristina Machado Motta
Affiliation:
Keywords: Chemotherapy, DNA binding drugs, kinetoplast, topoisomerases, trypanosomatids
Abstract: Many trypanosomatid protozoa, such as those belonging to the Trypanosoma and Leishmania genera cause serious diseases to man. Such parasites present an unusual feature, a mitochondrial DNA arranged in catenated circles, known as kinetoplast DNA (kDNA). The replication of kDNA network is a complex process, which involves many proteins. Some of them are classified as topoisomerases and play essential biological roles, not only on kDNA synthesis, but also in the dynamics of the network topology, constituting the main target for drugs in kinetoplast. DNA binding drugs are also reported as chemotherapeutic agents against trypanosomatid infections. This review summarizes what is known about kinetoplast as a potential chemotherapeutic target for trypanosomatid protozoa.
Export Options
About this article
Cite this article as:
Machado Motta Cristina Maria, Kinetoplast as a Potential Chemotherapeutic Target of Trypanosomatids, Current Pharmaceutical Design 2008; 14 (9) . https://dx.doi.org/10.2174/138161208784041051
DOI https://dx.doi.org/10.2174/138161208784041051 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Morpholine Based Diazenyl Chalcones: Synthesis, Antimicrobial Screening and Cytotoxicity Study
Anti-Cancer Agents in Medicinal Chemistry Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine
Anti-Cancer Agents in Medicinal Chemistry COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema
Current Respiratory Medicine Reviews MicroRNAs and Aging: Biomarkers or Therapeutic Targets?
Current Aging Science Cellular Signaling Crosstalk Between Multiple Receptors for Investigation of Pathophysiology in Multifactorial Diseases - What is Clinically-Relevant Crosstalk?
Current Medicinal Chemistry NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Detecting Growing Mammary Tumors with Monoclonal Antibodies Against Vascular Endothelial Growth Factor Receptor – 3
Current Radiopharmaceuticals Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Boron-Containing Compounds as Preventive and Chemotherapeutic Agents for Cancer
Anti-Cancer Agents in Medicinal Chemistry New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators
Current Cancer Therapy Reviews GRP78 Influences Chemoresistance and Prognosis in Cancer
Current Drug Targets An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Development of Radicicol Analogues
Current Cancer Drug Targets Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Current Pharmaceutical Design The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression
Anti-Cancer Agents in Medicinal Chemistry Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets